Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02789150 · ClinicalTrials.gov registry record · Early Phase 1
Outcomes of Renal Function in Hepatorenal Syndrome (HRS) Determined By Comparison of Target Mean Arterial Pressure (MAP) of 65 - 70 Mmhg Versus ≥ 85 Mmhg
A Early Phase 1 study of Hepatorenal Syndrome, sponsored by University of Louisville.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT02789150 is a Early Phase 1 study of Hepatorenal Syndrome that has completed, run by University of Louisville. The registered enrollment target is 18 participants, below the 421-participant average among 5 other Hepatorenal Syndrome trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02789150, a Early Phase 1 study of Hepatorenal Syndrome, has completed, sponsored by University of Louisville.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
Comparing renal outcomes based on a Mean Arterail Pressure (MAP) of 65-7085mmhg versus a MAP of greater than or equal to 85mmhg
Conditions Studied
Interventions
- DRUG Norepinephrine (Levophed)
Study Locations (1)
Kentucky
- University of Louisville - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2015-01 |
| Est. Completion | 2018-01-11 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02789150
The ClinicalTrials.gov registry entry for NCT02789150 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 421-participant average among 5 other Hepatorenal Syndrome trials with a reported enrollment target (96% lower). The listed sponsor is University of Louisville, which has 217 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatorenal Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Norepinephrine (Levophed) is the first listed.
NCT02789150 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT02789150 about?
NCT02789150 is a clinical study titled "Outcomes of Renal Function in Hepatorenal Syndrome (HRS) Determined By Comparison of Target Mean Arterial Pressure (MAP) of 65 - 70 Mmhg Versus ≥ 85 Mmhg". Comparing renal outcomes based on a Mean Arterail Pressure (MAP) of 65-7085mmhg versus a MAP of greater than or equal to 85mmhg
What is the current status of trial NCT02789150?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2015-01. Estimated completion is 2018-01-11.
What conditions does trial NCT02789150 study?
This clinical trial studies the following conditions: Hepatorenal Syndrome.
What interventions are being tested in trial NCT02789150?
The interventions under investigation include: Norepinephrine (Levophed) (DRUG).
Who is sponsoring clinical trial NCT02789150?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02789150 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatorenal Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Retrospective Analysis of Outcomes in Patients with Hepatorenal Syndrome At Methodist Dallas Medical Center
RECRUITING
-
Initial Resuscitation for Acute Kidney Injury in Cirrhosis
RECRUITING · NA
-
A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury
COMPLETED · Phase 2
-
Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE)
COMPLETED · Phase 3
-
International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.